Suven Life Sciences secures process patents in Europe, Japan and New Zealand

17 Aug 2017 Evaluate

Suven Life Sciences has secured one process patent from Europe, one process patent from Japan and one process patent from New Zealand corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

These process patents are for the company’s pipeline compounds which are in the class of selective 5-HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

127.80 -5.70 (-4.27%)
27-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1636.05
Dr. Reddys Lab 1240.00
Cipla 1313.20
Zydus Lifesciences 895.85
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×